77 results
8-K
EX-99.1
TVTX
Travere Therapeutics, Inc.
20 Feb 25
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
4:04pm
can be given once blood pressure has stabilized.
Acute Kidney Injury: Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin … system (RAS) can cause kidney injury. Patients whose kidney function may depend in part on the activity of the RAS (e.g., patients with renal artery
8-K
EX-99.1
TVTX
Travere Therapeutics, Inc.
13 Jan 25
Travere Therapeutics Provides Corporate Update and 2025 Outlook
7:30am
.
Acute Kidney Injury: Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system (RAS) can cause kidney injury. Patients whose … heart failure, or volume depletion) may be at particular risk of developing acute kidney injury on FILSPARI. Consider withholding or discontinuing
424B5
TVTX
Travere Therapeutics, Inc.
8 Nov 24
Prospectus supplement for primary offering
4:11pm
, non-immunosuppressive medication that directly targets glomerular injury in the kidney by blocking two critical pathways of IgAN disease progression
424B5
TVTX
Travere Therapeutics, Inc.
7 Nov 24
Prospectus supplement for primary offering
4:01pm
the patient’s treatment journey. FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury
8-K
EX-99.1
rhtbd4uwlry1xc166c
31 Oct 24
Travere Therapeutics Reports Third Quarter 2024 Financial Results
8:05am
8-K
n4qxcfbr2a40z8g5
5 Sep 24
Other Events
5:47pm
8-K
EX-10.1
kq2z plyb1lggjuda6h
17 Jul 23
Entry into a Material Definitive Agreement
8:07am
8-K/A
EX-10.1
nutnrabu0sord5tmx
17 Aug 22
Departure of Directors or Certain Officers
5:20pm